RG108 treatment increases the expression of anti-senescence genes, while p53 and p16 expressions are suppressed, in ALS patient-derived bone marrow mesenchymal stromal cells [111]; in addition, RG108 treatment of mice can activate the rejuvenation stemness gene hes5 [112]. This evidence concerns the gene TP53 and amyotrophic lateral sclerosis.